Future Journal of Pharmacy and Medical Sciences https://pharmasprings.com/fjpms <div> <img style="width: 100%;" src="https://pharmasprings.com/templates/frontend/pages/slideshow/slideshow.gif" /></div> <p align="justify">Future Journal of Pharmacy and Medical Sciences (FJPMS), with an ISSN pending application, is an initiative of Pharma Springs Publications. Slated for launch in 2023, FJPMS aims to bring together diverse experts from the pharmacy and medical sectors. Its core mission is to focus exclusively on the dissemination of breakthroughs and scholarly articles in Pharmaceuticals and Medical Sciences. Scheduled for quarterly issues, FJPMS is committed to publishing high-quality original research that contributes substantially to the advancement of scientific understanding in both Pharmaceutical and Medical disciplines.</p> en-US editorpharmasprings@gmail.com (Editor) editorpharmasprings@gmail.com (Editor) Tue, 23 Jul 2024 00:00:00 +0530 OJS 3.2.1.2 http://blogs.law.harvard.edu/tech/rss 60 Scurvy - Rediscovering a Forgotten Disease https://pharmasprings.com/fjpms/article/view/640 <p>Scurvy is a long-documented dietary deficit that results from inadequate vitamin C.&nbsp;Because of its part in the metabolic events of connective tissue production, it results in a diverse presentation that affects numerous organ systems.&nbsp;Prominent signs and symptoms include ecchymoses, arthralgias, skin pigmentation, decreased wound healing, and gingival bleeding. Due to increased consumption as well as supplementation of vitamin C, the incidence of scurvy has drastically decreased in contemporary times; yet, isolated cases still arise. It is primarily identified in the elderly and malnourished in industrialised nations, and it is linked to drinking, a low socioeconomic status, as well as unhealthful eating habits.&nbsp;Among other GI symptoms, gastrointestinal (GI) bleeding has been reported to be an uncommon cause of scurvy. Vitamin C supplements can effectively treat and prevent it. A crucial redox co-factor in the systems of plants and animals is ascorbic acid, sometimes known as vitamin C. Although ascorbic acid is produced in sufficient amounts by most species, it functions as a real vitamin in those that lack the enzymes needed for synthesis. A crucial component of several metabolic pathways is ascorbic acid. Ascorbic acid must be obtained by humans from diet. People who eat ascorbic acid-deficient diets get scurvy.</p> Vidyadhari Arava, Ashok Kumar V, Teja Divya Mangala, Divya Sree Bandi, Pavani Tummala, Ram Prathap Goud Porumamilla, Siva Prasad Tatiparthi, Swathi Krishna KV Copyright (c) 2024 © Future Journal of Pharmacy and Medical Sciences https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pharmasprings.com/fjpms/article/view/640 Tue, 23 Jul 2024 00:00:00 +0530 Development and bioavailability improvement of imiquimod in the form of solid lipid nanoparticles https://pharmasprings.com/fjpms/article/view/641 <p>Nanomaterials are the ideal carriers for biological applications because of their high bioavailability and biocompatibility. The primary focus of many researchers employing novel techniques has been fresh discoveries. Many methods have been used to create nanoparticles, which have potential applications in various illnesses. Solid Lipid Nanoparticle (SLN) drug delivery system has outstanding results in treating chronic diseases. Actinic keratoses (AK), known as sun keratoses or senile keratoses, are benign intraepithelial neoplasms caused by abnormal keratinocyte proliferation. Hence, in the present research, Imiquimod SLNs were fabricated using various concentrations of lipids, surfactants, and cryoprotectants. Cold high-pressure homogenization was shown to produce smaller particles with improved entrapment effectiveness. The Particle size ranges from (209.6±4.57 to 502.1±8.9 nm). Formulation IMB 3 which contain 1% w/w Glycerol Monostearate and 3% w/w Glyceryl Behenate as Lipid for SLNs preparation shows better results for Mean particle size (245.1±8.45), Zeta Potential (-41±1.2), PDI (0.39±0.03), % EE (64±0.79) and Loading Capacity (48±2.6) with % cumulative drug release of 89.74±3.5 after 24 hours.</p> Vareesha Karimella, Venugopalaiah Penabaka, Chandu Priya Lokku, Penchala Anitha Maddiletigadda, Mohamed Mujahith S, Afrin Shaik, Prapurna Chandra Yadala Copyright (c) 2024 © Future Journal of Pharmacy and Medical Sciences https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pharmasprings.com/fjpms/article/view/641 Tue, 23 Jul 2024 00:00:00 +0530 Formulation and Optimization of Propranolol Hydrochloride Oro-dispersable Tablets by Central Composite Design https://pharmasprings.com/fjpms/article/view/642 <p>The present work aimed&nbsp;to formulate and optimize&nbsp;propranolol HCL mouth tablets through experiment design. The scientific knowledge of input and output factors was assessed using the central composite design tool to create a design space for regulatory flexibility. The natural super disintegrant&nbsp;concentrations were chosen as the independent variables. The dependent variables were in vitro dispersion time and drug release %. FTIR tests showed drug and excipient compatibility. Precompression parameters showed that the flow characteristics were generally good. The direct compression method was used to manufacture the tablets, and all of the tablets made in the tests above met the predetermined limitations for pharmacotechnical characteristics. Dehydrated banana powder concentration increases led to a reduction in in vitro dispersion time and an increase in drug release percentage. According to kinetic studies, drug release from all formulations followed the first-order release. The outcomes proved that the suggested concept for creating Propranolol Hcl Mouth Melt Tablets with optimal qualities worked well.</p> Pratyusha Ande, Sahithi Challa, Meghana Chinthakayala, Bhoomika Jonnalagadda, Salman Syed, Prapurna Chandra Yadala Copyright (c) 2024 Future Journal of Pharmacy and Medical Sciences https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pharmasprings.com/fjpms/article/view/642 Sun, 28 Apr 2024 00:00:00 +0530